Delphine B.
- Country
- France
- Department
- Cardiology
Research Overview
- Evaluation of Seralutinib Efficacy and Safety in Pulmonary Arterial Hypertension: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial
- Long-term Safety and Efficacy Evaluation of Inhaled Seralutinib in Pulmonary Arterial Hypertension: An Open-label Extension Study
- Long-term Evaluation of Sotatercept in Combination with Background Therapy for Pulmonary Arterial Hypertension in Adult Patients
Data & Insights
Has run more than one trial at 90 of 189 partner sites.
Specializations
Pulmonary Arterial Hypertension Management
The investigator specializes in treating pulmonary arterial hypertension (PAH), with particular emphasis on evaluating novel therapeutic approaches for patients at various disease stages.
- Advanced PAH Treatment Protocols
- Long-term Disease Management
- Risk Assessment Strategies
Their research encompasses both newly diagnosed and ongoing PAH cases, focusing on optimizing treatment outcomes.
Cardiopulmonary Therapeutics
The investigator focuses on innovative treatments for combined postcapillary and precapillary pulmonary hypertension, particularly in relation to heart failure with preserved ejection fraction.
- Exercise Capacity Assessment
- Pulmonary Vascular Resistance
- Cardiopulmonary Hemodynamics
Their work extends to evaluating both oral and inhaled therapeutic interventions for pulmonary vascular diseases.
Clinical Safety and Efficacy
The investigator conducts extensive research into the long-term safety and tolerability of emerging treatments for pulmonary hypertension conditions.
- Treatment Safety Monitoring
- Extended Therapy Evaluation
- Drug Efficacy Assessment
Their expertise includes evaluating therapeutic interventions across various treatment durations and patient populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.